Indivior Pharmaceuticals (INDV) Non-Current Debt (2021 - 2026)

Indivior Pharmaceuticals' Non-Current Debt history runs 6 years deep, the most recent figure standing at $486.0 million for Q1 2026.

• On a quarterly basis, Non-Current Debt rose 56.27% year-over-year to $486.0 million in Q1 2026; TTM through Mar 2026 was $486.0 million, a 56.27% increase from a year earlier, with the FY2025 full-year figure at $290.0 million, down 7.94% from the prior year.
• Non-Current Debt rose to $486.0 million in Q1 2026 per INDV's latest filing, from $290.0 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $486.0 million in Q1 2026 and bottomed at $237.0 million in Q4 2022.
• The 5-year median for Non-Current Debt is $306.0 million (2025), against an average of $311.0 million.
• Across the five-year window, Non-Current Debt slipped 7.94% in 2025 and soared 56.27% in 2026, its largest moves.
• Year by year, Non-Current Debt stood at $237.0 million in 2022, then changed by 0.0% to $237.0 million in 2023, then soared by 32.91% to $315.0 million in 2024, then declined by 7.94% to $290.0 million in 2025, then soared by 67.59% to $486.0 million in 2026.
• Per Business Quant, the three latest INDV Non-Current Debt figures stand at $486.0 million (Q1 2026), $290.0 million (Q4 2025), and $304.0 million (Q3 2025).